These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27688470)

  • 1. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
    Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
    J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hedgehog inhibitor sonidegib potentiates
    Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
    BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
    Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
    Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
    Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
    Thakral P; Sen I; Das SS; Manda D; Cb V; Malik D
    Br J Radiol; 2021 Oct; 94(1126):20210403. PubMed ID: 34357794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [
    Warfvinge CF; Gustafsson J; Roth D; Tennvall J; Svensson J; Bernhardt P; Åkesson A; Wieslander E; Sundlöv A; Sjögreen Gleisner K
    J Nucl Med; 2024 Jul; 65(7):1070-1075. PubMed ID: 38724277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
    Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
    Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice.
    Svensson J; Mölne J; Forssell-Aronsson E; Konijnenberg M; Bernhardt P
    Nucl Med Biol; 2012 Aug; 39(6):756-62. PubMed ID: 22445743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
    Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
    Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S
    Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution, Pharmacokinetics, and Dosimetry of
    Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
    J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
    Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Trial of
    Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
    N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.